Therapeutic antibodies will always be too expensive for low- and middle-income countries, unless manufacturers embrace more cost-efficient production tech. So says Peter Gardner, scientific director ...
After the safety and efficacy of a biopharmaceutical, the efficiency of bioprocessing it might be the most crucial aspect. As Aleksandr Pogodaev, PhD—principal scientist in pharmacometrics, Novartis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results